This explains the potential therapeutic effect of menin inhibitors (e.g., Revumenib, Ziftomenib) [24,25] and DOTL1 inhibitors (e.g., Pinometostat) in this adverse disease subtype of AML [21,26,27,28]. Here, MEN1 is linked to acute myeloid leukemia.